A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan.
It will also look at what side effects happen when these drugs are given together. A side
effect is anything a drug does besides treating cancer.
Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to
other parts of the body (metastatic) or cannot be removed completely with surgery
(unresectable). All participants will get both tucatinib and trastuzumab deruxtecan.